DIFF Biotech’s Innovative Nasal Spray Influenza Vaccine Receives Clinical Trial Approval, Introducing a New Attenuation Pathway

2026-02-09 - 13:38

HANGZHOU, China, Feb. 9, 2026 /PRNewswire/ — Zhejiang Difference Biological Technology Co., Ltd. (DIFF Biotech) announced that its proprietary nasal spray influenza attenuated live vaccine, DIFF-flu, has recently received clinical trial approval as a Class 1.2 innovative vaccine from China’s National Medical Products Administration (NMPA). As the first domestically self-developed nasal spray influenza vaccine in